Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Water for Injection (WFI) Systems Usage – V 2.0

Posted on By


Biosimilars: SOP for Water for Injection (WFI) Systems Usage – V 2.0


Standard Operating Procedure for Water for Injection (WFI) Systems Usage in Biosimilar Manufacturing

Department Biosimilars
SOP No. SOP/BS/127/2025
Supersedes SOP/BS/127/2022
Page No. Page 1 of 12
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To establish a procedure for the usage, monitoring, and documentation of Water for Injection (WFI) in biosimilar manufacturing processes, ensuring compliance with GMP, pharmacopeial, and microbiological standards.

2. Scope

This SOP applies to all activities involving the use of WFI from generation, storage, distribution, and dispensing points in the biosimilar facility’s upstream and downstream areas.

3. Responsibilities

  • Engineering: Operate and maintain the WFI generation and distribution system. Perform sanitization.
  • Production: Use WFI as per batch requirement and record usage.
  • QC: Perform sampling and testing of WFI at designated user points.
  • QA: Review usage logs and test results. Release WFI lines after sanitization.

4. Accountability

The Head of Engineering is accountable for ensuring uninterrupted WFI supply and system compliance. The Head of QA ensures release of sanitized lines and compliance to specifications.

5. Procedure

5.1 WFI Generation and Storage

  1. Generate WFI through multi-effect distillation system or vapor compression distiller.
  2. Store WFI in jacketed, temperature-controlled storage tanks (≥80°C).
  3. Record system temperature, pressure, and conductivity continuously (Annexure-1).

5.2 WFI Distribution and Use

  1. WFI to be used only from approved user points with validated loop design.
  2. Before each use:
    • Flush for 30–60 seconds
    • Check point-of-use temperature (must be ≥70°C for hot loops or ≤25°C for cold loops)
  3. Use sterile hoses/tubing, and never reuse unless validated.
  4. Document WFI usage in Annexure-2: WFI Usage Logbook.

5.3 Microbiological and Chemical Testing

  1. Perform sampling from user points as per validation matrix:
    • Daily: Conductivity, TOC
    • Weekly: Microbial count
    • Monthly: Endotoxin testing
  2. QC to record results in Annexure-3: WFI Quality Summary Log.
  3. Out-of-specification results to be managed as per deviation handling SOP.

5.4 Sanitization and Maintenance

  1. Perform periodic heat sanitization or chemical sanitization of storage and distribution system.
  2. Record details including temperature, duration, and outcome in Annexure-4.
  3. QA to verify successful sanitization before releasing the line.

6. Abbreviations

  • WFI: Water for Injection
  • TOC: Total Organic Carbon
  • QC: Quality Control
  • QA: Quality Assurance

7. Documents

  1. WFI Generation and Monitoring Log – Annexure-1
  2. WFI Usage Logbook – Annexure-2
  3. WFI Quality Summary Log – Annexure-3
  4. Sanitization Record – Annexure-4

8. References

  • USP & EP Specifications for Water for Injection
  • WHO TRS 970 – Annex 2
  • ISPE Baseline Guide: Water and Steam Systems

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: WFI Generation and Monitoring Log

Date Time Temp (°C) Conductivity Pressure Remarks
04/05/2025 10:00 81.5 0.6 µS/cm 1.8 bar OK

Annexure-2: WFI Usage Logbook

Date Location Volume Used Flushed (Y/N) Used By
04/05/2025 Media Prep 15 L Y Ajay Verma

Annexure-3: WFI Quality Summary Log

Date Point ID Conductivity TOC Microbial Endotoxin
03/05/2025 WFI-POU-03 0.7 350 ppb 0 CFU/mL 0.01 EU/mL

Annexure-4: Sanitization Record

Date Type Temp/Agent Duration Performed By QA Review
01/05/2025 Heat 85°C 1 hr Sunita Reddy Approved

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Clarified daily TOC/conductivity and added sanitization annexure GMP compliance
See also  Biosimilars: SOP for Harmonizing MCB/WCB Data with QA System - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Gel Manufacturing: SOP for Accelerated Stability Testing of Gels – V 2.0
Next Post: Creams: SOP for Reviewing Validation Master Plans – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version